Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370
18/09/2023 12:36
Sept 18 (Reuters) - ContraFect Corp CFRX.O :
* CONTRAFECT ANNOUNCES SUBMISSION OF IND APPLICATION TO THE
FDA
FOR ITS DEVELOPMENT CANDIDATE CF-370
* CONTRAFECT CORP - EXPECT TO INITIATE PHASE 1
FIRST-IN-HUMAN
STUDIES IN US LATER THIS YEAR
* CONTRAFECT CORP- FDA WILL REVIEW APPLICATION AND DETERMINE
ACCEPTABILITY OF DATA BEFORE CF-370 BEGINS FIRST CLINICAL TRIAL
Source text for Eikon: ID:nGNX3M4YqN
Further company coverage: CFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370